OrganiGram (OGI) Stock Forecast, Price & News

OrganiGram (NASDAQ:OGI) Frequently Asked Questions

Is OrganiGram a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OrganiGram stock.
View analyst ratings for OrganiGram or view top-rated stocks.

When is OrganiGram's next earnings date?

OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, July 12th 2022.
View our earnings forecast for OrganiGram.

How were OrganiGram's earnings last quarter?

OrganiGram Holdings Inc. (NASDAQ:OGI) released its earnings results on Tuesday, April, 12th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02). The company earned $25.04 million during the quarter, compared to analyst estimates of $24.28 million. OrganiGram had a negative net margin of 32.87% and a negative trailing twelve-month return on equity of 12.28%. During the same quarter last year, the business earned ($0.09) earnings per share.
View OrganiGram's earnings history.

What price target have analysts set for OGI?

7 equities research analysts have issued 12-month target prices for OrganiGram's stock. Their forecasts range from $2.25 to $5.30. On average, they anticipate OrganiGram's stock price to reach $3.43 in the next year. This suggests a possible upside of 183.1% from the stock's current price.
View analysts' price targets for OrganiGram or view top-rated stocks among Wall Street analysts.

Who are OrganiGram's key executives?

OrganiGram's management team includes the following people:

• Mr. Derrick W. West CPA, CPA, (CA), Chief Financial Officer (Age 55, Pay $241.72k)
• Ms. Helen Martin, Chief Legal Officer & Corp. Sec. (Age 44, Pay $226.39k)
• Mr. Gregory Engel, Special Advisor (Age 57, Pay $452.87k)
• Mr. Timothy Emberg, Chief Revenue Officer
• Mr. Paolo De Luca C.A., C.F.A, Chief Strategy Officer (Age 49, Pay $238.52k)
• Ms. Beena G. Goldenberg, CEO & Director (Age 59)
• Ms. Nathalie Batten, VP of Operations
• Amy Schwalm, VP of Investor Relations
• Ms. Megan Amber McCrae, Sr. VP of Marketing & Communications
• Tina Shannon, VP of HR

Who are some of OrganiGram's key competitors?

Some companies that are related to OrganiGram include Travere Therapeutics (TVTX), Xenon Pharmaceuticals (XENE), Supernus Pharmaceuticals (SUPN), Taro Pharmaceutical Industries (TARO), Dynavax Technologies (DVAX), Xencor (XNCR), Ligand Pharmaceuticals (LGND), Arcus Biosciences (RCUS), Sierra Oncology (SRRA), BELLUS Health (BLUSF), 23andMe (ME), IVERIC bio (ISEE), Axsome Therapeutics (AXSM), Prothena (PRTA) and Prometheus Biosciences (RXDX).
View all of OGI's competitors.

What other stocks do shareholders of OrganiGram own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB), (CGC), Auxly Cannabis Group (CBWTF), Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), CNBX Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

What is OrganiGram's stock symbol?

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Who are OrganiGram's major shareholders?

OrganiGram's stock is owned by many different retail and institutional investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (1.43%), Bank of Montreal Can (0.73%), Goldman Sachs Group Inc. (0.28%), Connor Clark & Lunn Investment Management Ltd. (0.20%), Swiss National Bank (0.19%) and Vontobel Holding Ltd. (0.17%).

Which institutional investors are selling OrganiGram stock?

OGI stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Connor Clark & Lunn Investment Management Ltd., Mirae Asset Global Investments Co. Ltd., UBS Group AG, Cutler Group LP, and SIG North Trading ULC.

Which institutional investors are buying OrganiGram stock?

OGI stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Renaissance Technologies LLC, Vanguard Group Inc., Cibc World Market Inc., Mackenzie Financial Corp, Swiss National Bank, Flow Traders U.S. LLC, and Group One Trading L.P..

How do I buy shares of OrganiGram?

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrganiGram's stock price today?

One share of OGI stock can currently be purchased for approximately $1.21.

How much money does OrganiGram make?

OrganiGram has a market capitalization of $379.56 million and generates $62.43 million in revenue each year. The company earns $-103.09 million in net income (profit) each year or ($0.09) on an earnings per share basis.

How many employees does OrganiGram have?

OrganiGram employs 841 workers across the globe.

What is OrganiGram's official website?

The official website for OrganiGram is www.organigram.ca.

How can I contact OrganiGram?

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at (844) 644-4726.